Literature DB >> 15206727

Accumulation of quinolinic acid with neuroinflammation: does it mean excitotoxicity?

Tiho P Obrenovitch1, Jutta Urenjak.   

Abstract

The quinolinic acid (QUIN) accumulation that is associated with neuroinflammation is often considered capable of promoting excitotoxic neuronal damage, but QUIN is a relatively weak agonist of N-methyl-D-aspartate (NMDA) receptors. Our study aimed to determine, in vivo, which extracellular concentrations of QUIN must be reached to initiate electrophysiological changes indicative of excitotoxic stress in the cerebral cortex of rats, under normal conditions and when superimposed to a challenge involving NMDA-receptor activation, i.e. repeated cortical spreading depression (CSD). Our experimental strategy relied on microdialysis probes incorporating an electrode, implanted in the brain of halothane-anaesthetised rats. These devices were used to apply QUIN or NMDA locally to the cortical area under study (with or without co-perfusion of high K+ for repetitive induction of CSD), and to record the associated changes in the extracellular DC potential (for information on the membrane polarisation of the cellular population surrounding the probe) and lactate (for the detection of increased local energy demand). The extracellular EC50 for induction of local depolarisation in the normal cortex was around 30 times higher than the extracellular QUIN levels measured in the immunoactivated brain of gerbils. Within the range of concentrations 0.03 to 0.3 mM in the perfusion medium, QUIN suppressed concentration-dependently the elicitation of CSD by K+, presumably because of NMDA-receptor desensitisation. Finally, on-line monitoring of changes in extracellular lactate with local application of QUIN indicated that extracellular concentration of QUIN in the low micromolar range are well tolerated by the brain parenchyma, at least in cortical regions. All these data do not support the notion that QUIN accumulation adds an excitotoxic component to neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15206727     DOI: 10.1007/978-1-4615-0135-0_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?

Authors:  Robert Dantzer; Adam K Walker
Journal:  J Neural Transm (Vienna)       Date:  2014-03-15       Impact factor: 3.575

Review 2.  Kynurenines and headache.

Authors:  Arpád Párdutz; Annamária Fejes; Zsuzsanna Bohár; Lilla Tar; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

Review 3.  Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.

Authors:  Martina Curto; Luana Lionetto; Francesco Fazio; Dimos-Dimitrios Mitsikostas; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2015-02-24       Impact factor: 3.397

Review 4.  Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes.

Authors:  Nady Braidy; Jade Berg; James Clement; Fatemeh Khorshidi; Anne Poljak; Tharusha Jayasena; Ross Grant; Perminder Sachdev
Journal:  Antioxid Redox Signal       Date:  2018-05-11       Impact factor: 8.401

5.  Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives.

Authors:  Annamária Fejes; Arpád Párdutz; József Toldi; László Vécsei
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

6.  Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period.

Authors:  Bernadett Tuka; Aliz Nyári; Edina Katalin Cseh; Tamás Körtési; Dániel Veréb; Ferenc Tömösi; Gábor Kecskeméti; Tamás Janáky; János Tajti; László Vécsei
Journal:  J Headache Pain       Date:  2021-06-25       Impact factor: 7.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.